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Introduction 
Chronic myelogenous leukemia (CML) is a 
myeloproliferative disorder resulting from a reciprocal 
translocation between chromosomes 9 and 22 (t(9;22) 
or Philadelphia chromosome) that results in the coding 
of an abnormal fusion protein (BCR-ABL) with 
deregulated tyrosine kinase activity [1]. Without 
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Abstract  
Chronic myelogenous leukemia (CML) is a hematological stem-cell disorder characterized by the expression of the 
BCR-ABL fusion protein, a constitutively active tyrosine kinase that causes pathogenesis. The development of tyrosine 
kinase inhibitors (TKIs) targeting the BCR-ABL oncogene has proven an effective approach to treat CML, but a 
non-negligible proportion of patients develop a resistance to this class of drugs. Of note, the T315I mutant of BCR-ABL 
is resistant to all known TKIs, with the noticeable exception of ponatinib. To address this unmet medical need, a new 
series of compounds was designed and tested for anti-tumor effects against BCR-ABLT315I CML. The effects of three 
OriBase Pharma compounds (OR1001, OR1002 and OR1003) on the kinase activity of wild-type and mutant BCR-ABL 
proteins, on cell proliferation and on the growth of subcutaneous xenografts of CML cells in athymic mice were 
investigated. In vitro, the three compounds were potent inhibitors of both ABL and c-SRC kinases and of the main 
mutants of ABL, including T315I. The three compounds inhibited the proliferation of cell lines expressing the wild-type 
and several mutated forms of BCR-ABL, including T315I. Finally, in a mouse xenograft model, OR1001, was found to 
significantly reduce tumor growth. These data support the potential of OR1001 as an effective therapy for the 
treatment of de novo and TKI-resistant patients. 
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therapy, CML progresses from a chronic phase (CP) to 
an accelerated phase (AP) and then to a blast phase 
(BP). Although it is a rare disease, CML was the focus 
of intensive investigations as a disease model against 
which to design tyrosine kinase inhibitors (TKIs). 
Three TKIs have thus received approval for the 
treatment of CML. Imatinib was the first TKI to be 
approved for CML patients, and it revolutionized the 
standard of care [2]. Dasatinib and nilotinib were 
developed as second-line treatments for cases of 
imatinib failure [3]. They are active against most, but 
not all, ABL tyrosine kinase domain mutations that 
impart resistance to imatinib. As expected, 
second-generation TKIs were found to be effective in 
the first-line setting and have received regulatory 
approval for that indication.  
Although imatinib, nilotinib and dasatinib share a 
common mechanism of action, namely tyrosine kinase 
inhibition, they have important differences. From a 
mechanistic standpoint, both imatinib and nilotinib 
bind to the inactive conformation of the ABL kinase, 
whereas dasatinib binds to multiple conformations [3]. 
Nilotinib is up to 50 times more potent than imatinib 
in inhibiting BCR-ABL in cell proliferation assays, 
whereas dasatinib is up to 325 times more potent [4,5]. 
Of the three agents, dasatinib is a dual BCR-ABL and 
SRC inhibitor, and nilotinib is the most selective 
inhibitor. ABL kinase domain mutations constitute the 
most common mechanism of resistance to imatinib 
(BCR-ABL-dependent imatinib resistance) [6]. More 
than 50 of these mutations have been described [7–10]. 
Both dasatinib and nilotinib are active against all 
known imatinib-resistant mutations except the T315I 
mutation, which imparts resistance to all three agents. 
However, dasatinib and nilotinib have differences in 
their potency against specific non-T315I mutations [5]. 
Other mechanisms may contribute to imatinib 
resistance, and reports have demonstrated a 
requirement for SRC kinase activity in BCR-ABL 
transformation and oncogenic signal transduction 
[11,12]. Some members of the SRC family of kinases 
(SFKs) are overexpressed in isolated imatinib-resistant 
patient cell lines, suggesting that SFKs may be 
involved in BCR-ABL-independent imatinib 
resistance [13,14].  
To date, there are not yet any clinically approved 
T315I inhibitors on the market. Thus, alternative 
approaches for the inhibition of the T315I mutant, 
which represents 15-20% of all clinically observed 
mutants, are of great pharmacological and medical 
interest [15,16]. As an example, ponatinib, a 
pan-BCR-ABL TKI still under investigation, was 
developed to overcome the T315I mutation in resistant 
CML patients. The development of new compounds 
that are able to counteract imatinib resistance in 
inhibiting the SRC kinase pathways and all known 
BCR-ABL mutations, including T315I, remains a 
pharmacological challenge for many researchers. In 
this context, we have designed new optimized series of 
ABL and c-SRC kinase inhibitors with enhanced 
affinity and potency against the main ABL kinase 
domain mutations, including T315I. These inhibitors 
are potential new therapies for CML, Philadelphia 
chromosome (Ph)-positive acute lymphoblastic 
leukemia (ALL) and patients that do not respond or 
become resistant to currently approved agents.  
Materials and Methods 
Inhibitors and reagents 
Inhibitor stock solutions in DMSO (10 mM) were 
stored at -20°C, and diluted just before use for in vitro 
assays. Imatinib and dasatinib were purchased from 
LC Laboratories (Woburn, MA, USA). OR1001, 
OR1002 and OR1003 were designed and synthesized 
at OriBase Pharma laboratories. Cell reagents and 
MTT reagent (thiazolyl blue tetrazolium bromide) 
were purchased from Sigma-Aldrich (Saint Louis, MO, 
USA). 
Cell lines 
Murine Ba/F3 BCR-ABLWT, Ba/F3 BCR-ABLT315I, 
Ba/F3 BCR-ABLG250A, Ba/F3 BCR-ABLG250E, Ba/F3 
BCR-ABLE255K+M351T and Ba/F3 BCR-ABLG250A+E279N, 
a kind gift of Dr. JM Pasquet, were grown in 
RPMI-1640 medium. Da1-3b BCR-ABLWT and 
Da1-3b BCR-ABL E255K+T315I, provided by Dr. Bruno 
Quesnel [17], were grown in DMEM medium (high 
glucose) supplemented with 1% pyruvate sodium and 
1% non-essential amino acids. All media were 
supplemented with 10% heat-inactivated fetal bovine 
serum and penicillin/streptomycin. Cells were 
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maintained in a humidified incubator at 37°C with 5% 
CO2. 
In vitro kinase assays 
The biochemical activity of compounds was measured 
using Invitrogen's SelectScreen® Biochemical Kinase 
Profiling Service (Life Technologies Ltd., Paisley, UK). 
The in vitro IC50 values (IC50 represents the 
concentration of a compound that is required for 50% 
inhibition in vitro of the kinase activity) were 
determined at the ATP Km concentration. 
Cell proliferation assays 
Murine Ba/F3 BCR-ABLWT, Ba/F3 BCR-ABLT315I, 
Ba/F3 BCR-ABLG250A, Ba/F3 BCR-ABLE255K+M351T (1 x 
104 cells/well), Ba/F3 BCR-ABLG250E, Ba/F3 
BCR-ABLG250A+E279N (2 x 104 cells/well), Da1-3b 
BCR-ABLWT and Da1-3b BCR-ABLE255K+T315I (5 x 103 
cells/well) cell lines were distributed in 96-well plates 
and incubating in duplicate with escalating 
concentrations (1 pM to 10 µM) of compounds for 72 
hr. Cell proliferation was measured using MTT 
(3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide). The EC50 values (EC50 represents the 
concentration of a compound that is required for 50% 
inhibition of the cellular proliferation and/or cellular 
viability) were calculated from sigmoidal 
dose-response curves utilizing Prism 5.0 from 
Graph-Pad Software (GraphPad Software,  La Jolla, 
CA, USA), with values normalized to those of 
DMSO-treated control wells (0%) and 1% SDS control 
wells (100%). 
In vivo efficacy studies  
The xenograft mouse model of imatinib-resistant 
leukemia was prepared by subcutaneously injecting 
Ba/F3 BCR-ABLT315I (1 x 108 cell/mL sterile PBS) into 
the right flank of athymic nude male mice (HSD, 6-7 
weeks old). When the tumor volume reached 
approximately 50 mm3, mice were assigned randomly 
to either vehicle alone or OR1001, OR1002 or OR1003 
treatment groups (five mice per group). Mice were 
treated with either vehicle (DMSO) or compounds (40 
mg/kg q.d.; per os for 11 consecutive days). Tumor 
volumes in mm3 were determined three times a week 
with a digital caliper and calculated using the following 
formula: Tumor Volume (mm3) = length (mm) x width 
(mm) x width (mm) x ½. Body weight was measured 
three times a week, and mice were observed daily for 
monitoring signs of stress to detect possible toxicities. 
One-way ANOVA was used for statistical comparisons. 
Data were analyzed with Prism 5.0b (GraphPad 
Software) by one-way ANOVA with Bonferroni post 
hoc.  
Pharmacokinetics 
The pharmacokinetic profile of OR1001 and OR1003 
was assessed in Swiss male mice around 5 weeks old 
after single intravenous (IV) or oral (PO) dosing. For 
the intravenous route of administration, the compounds 
were dosed at 2 mg/kg using a PEG400/DMA 
(polyethylene glycol 400 / dimethyl acetamide) 2/1 
w/w solution. For oral gavage, the compounds were 
dosed at 20 mg/kg in a PEG400 suspension. Blood 
samples were collected at various time points and the 
compound concentrations in plasma determined by an 
internal standard LC/MS/MS method using protein 
precipitation and calibration standards prepared in 
blank mouse plasma. Reported concentrations are 
average values from 2-mice/time point/dose group. 
Results 
Inhibitory effect of compounds on ABL and 
c-SRC kinases activities in vitro  
We have previously reported the use of a rational 
fragment-based drug design approach to design new 
dual inhibitors of ABL and c-SRC kinases [18]. Three 
optimized compounds (OR1001, OR1002 and 
OR1003) potently inhibited native ABL and c-SRC 
kinase activities in biochemical assays (Table 1). All 
three inhibitors reduced the enzymatic activity of 
wild-type ABL and were also effective against the 
ABLT315I mutant with IC50 values in the nanomolar 
range. The three compounds also had potent inhibitory 
effects on the other imatinib-resistant ABL mutants 
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tested, including ABLG250E, ABLY253F and ABLE255K, 
establishing that they target directly native ABL and 
c-SRC kinases and also mutants of ABL kinase, 
including T315I. 
Table 1 Inhibitory activity (IC50 in nM) of OR1001, 
OR1002 and OR1003 on isolated tyrosine kinases 
Kinase OR1001 OR1002 OR1003 
ABL 2.9 5.7 0.7 
c-SRC 7.2 40.3 17.9 
ABLE255K 7.6 73.0 8.6 
ABLG250E 7.6 46.1 6.9 
ABLY253F 3.4 51.1 4.8 
ABLT315I 110.0 384.0 62.3 
Growth inhibition of cells expressing native or 
mutant BCR-ABL 
Cellular proliferation assays were performed with 
murine Ba/F3 cells 
expressing native BCR-ABL or mutated forms of 
BCR-ABL, and murine Da1-3b cells expressing native 
BCR-ABL or the E255K+T315I double mutated form 
of BCR-ABL (Figure 1). All compounds inhibited the 
proliferation of Ba/F3 and Da1-3b cells expressing 
wild-type BCR-ABL in a dose-dependent manner. In 
all cell lines and all BCR-ABL mutants, the 
compounds exhibited an antiproliferative activity at 
least 10 times more potent than that of imatinib. The 
EC50 values for OR1001, OR1002 and OR1003 were 
very close to that of dasatinib in each cell line, except 
in the BCR-ABLG250E, BCR-ABLT315I and 
BCR-ABLE255K+T315I cell lines for which the 
compounds exhibited a better antiproliferative effect 
than dasatinib (EC50 between 2 to 200 times lower 
than the EC50 of dasatinib). In the Ba/F3 
BCR-ABLT315I cell line, OR1001, OR1002 and 
OR1003 were, respectively, 10, 150 and 80 times more 
potent than dasatinib (Table 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Inhibitory activity of OR1001, OR1002 and OR1003 on cell line proliferation using Ba/F3 or Da1-3b cells 
expressing BCR-ABL wild-type or carrying either a single or double mutation. Cell viability was assessed by tetrazolium dye 
assay 72 h after drug treatment.  
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Table 2 EC50 values (nM) of OR1001, OR1002 and OR1003 on cell line proliferation.  
EC50 values are the mean of two experiments using duplicate wells. 
Cell line OR1001 OR1002 OR1003 Imatinib Dasatinib 
Ba/F3 BCR-ABLWT 1.8 0.6 1.1 29.0 0.1 
Ba/F3 BCR-ABLG250A 3.3 0.5 0.9 109.5 0.1 
Ba/F3 BCR-ABLG250E 484.1 17.0 44.1 4510.0 3870.0 
Ba/F3 BCR-ABLT315I  244.0 15.4 29.5 3798.0 2388.0 
Ba/F3 BCR-ABLG250A+E279N 1.7 0.2 0.5 36.7 0.1 
Ba/F3 BCR-ABLE255K+M351T 13.6 4.1 7.8 3815.0 0.7 
Da1-3b BCR-ABLWT 0.8 0.4 0.4 24.6 0.1 
Da1-3b BCR-ABLE255K+T315I 1109.0 265.6 291.3 3895.0 2054.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Anti-tumor activity of OR1001, OR1002 and OR1003 in mice bearing Ba/F3 BCR-ABLT315I subcutaneous tumors. 
Mice groups (n=5) were orally and daily dosed with either vehicle alone (DMSO) or compounds at 40 mg/kg for 11 days. 
Body weight and tumor volume were measured three times a week; tumors were weighed at the end of the study. **P<0.01 
versus vehicle-treated group.  
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Oral in vivo anticancer activity 
Based on their high biochemical inhibitory effect and 
good antiproliferative activity in vitro, OR1001, 
OR1002 and OR1003 were assessed for anticancer 
activity in vivo in a Ba/F3 BCR-ABLT315I tumor model 
in athymic mice. Three days after implantation (when 
tumors reached approximately 50 mm3), mice were 
treated daily with an oral dose of 40 mg/kg of OR1001, 
OR1002 or OR1003 for 11 days. Mice bearing Ba/F3 
BCR-ABLT315I cells tolerated daily administration of 
all compounds with no obvious evidence of toxicity as 
shown by no evident loss of weight during the study 
(Figure 2). Treatment with OR1001 led to significant 
tumor growth inhibition (TGI) close to 65% when 
compared to the vehicle-treated mouse group. As a 
consequence of the in vivo activity of OR1001, 
macroscopic examination at the end of the study 
indicated that the tumors of OR1001-treated mice 
were not vascularized (not shown). Importantly, in 
contrast to the mice treated with vehicle alone, no 
evidence of splenomegaly was detected in 
OR1001-treated mice (data not shown). All animals 
were necropsied and inspected and no gross 
anatomical abnormalities were observed (liver, kidney, 
pancreas, heart, intestine …). 
Pharmacokinetics 
In order to compare the pharmacokinetic properties of 
OR1001 and OR1003, their main pharmacokinetic 
(PK) parameters were evaluated in mice following 
intravenous (IV) or oral (PO) dosing (Table 3). In mice 
orally administered at a dose of 20 mg/kg, the 
maximum concentrations (Cmax) of OR1001 and 
OR1003 were obtained 30 minutes after dosing and 
reached 127 ng/mL (209 nM) and 239 ng/mL (402 
nM) respectively. Area under the curve (AUC)0-∞ was 
1125 ng·h/mL for OR1001 and 816 ng·h/mL for 
OR1003 corresponding to an estimated total exposure 
of 1.9 µM·h and 1.4 µM·h respectively. The half-lives 
(T1/2) and the bioavailability values (F) were similar 
for both compounds (3.5 hours and 12 % respectively).    
    Table 3 Mouse PK parameters following  
oral dosing at 20 mg/kg  
Compound Cmax 
 
Tmax 
 
AUC0-∞ 
  
 
T1/2 
 
F 
 OR1001 127 0.5 1125 3.6 12 
OR1003 239 0.5 816 3.5 12 
     
  These results demonstrate that the animal exposure 
represented by the AUC values exceeding by more 
than 15 times the in vitro IC50 values for SRC and all 
tested ABL mutants is sustained in mice at the oral 
dose of 20 mg/kg. According to these results, OR1001 
and OR1003 present similar pharmacokinetic profiles 
in Swiss mice. 
Discussion 
Resistance to imatinib in CML patients is classified as 
primary (i.e., no response from the onset of therapy) or 
secondary (i.e., following achievement of an objective 
response). Secondary resistances are usually attributed 
to point mutations in the kinase domain of BCR-ABL 
[19]. Numerous mutations have been identified 
throughout the ABL sequence and led to the 
development of new generations of inhibitors. 
However, none of the currently approved TKIs (i.e., 
imatinib, dasatinib and nilotinib) are active against the 
particularly aggressive T315I BCR-ABL mutation [15]. 
Although ponatinib, a third-generation BCR-ABL 
inhibitor, demonstrated significant clinical activity 
against the T315I mutation, important challenges 
remain. Further efforts are still needed to manage TKI 
side effects, improve the depth of cytogenetic and 
molecular responses and time to treatment response 
and then understand and override 
BCR-ABL-independent mechanisms of resistance. As 
an example of the latter type of resistance, many 
results indicate that BCR-ABL and SRC kinases 
interact with each other [20,21] and that SFKs play 
important roles in both CML progression and imatinib 
resistance [22,23]. In this context, the objective of this 
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study was to develop newer and more potent 
pan-BCR-ABL and c-SRC inhibitors able to target the 
native and mutated forms of BCR-ABL. 
In this study, we investigated the in vitro and in vivo 
effects of three synthetic small-molecule inhibitors of 
BCR-ABL and c-SRC kinases [18]. All OriBase 
Pharma compounds inhibited native ABL, native 
c-SRC kinase and a panel of clinically relevant 
mutants of ABL, including T315I, in vitro with IC50 
values in the nanomolar range. All inhibitors exhibited 
anti-leukemic effects against cell lines expressing 
wild-type BCR-ABL and single or double mutants of 
BCR-ABL. In vivo, only OR1001 significantly 
induced a decrease of tumor growth in xenografted 
mice bearing BCR-ABLT315I tumors while similar 
pharmacokinetic profiles for OR1001 and OR1003 
were obtained in Swiss mice. This unexpected greater 
in vivo activity of OR1001 compared to OR1002 and 
OR1003 was not consistent with the anti-proliferative 
activities and several hypotheses can be proposed. 
Firstly, the mice strain and the dose used to evaluate 
the PK parameters of OR1001 and OR1003 are 
different from those used for the efficacy studies. 
Possible strain differences between Swiss and athymic 
nude mice may affect the drug disposition and, the 
dose proportionality of the pharmacokinetics of 
compounds remains to define. A second hypothesis is 
that OR1001 could exhibit better ADME (Absorption, 
Distribution, Metabolism and Excretion) properties, 
such as a higher level of distribution to the tumor or 
the formation of one or several highly active 
metabolite(s), which give OR1001 the best anti-tumor 
effect. Another hypothesis is that OR1001 could 
present a secondary pharmacodynamic activity with a 
high activity against other anti-tumor targets of interest, 
other kinases as well as other molecular targets, 
conferring an added in vivo anti-tumor activity to 
OR1001. 
Additional studies are ongoing to investigate the 
pharmacokinetic properties, dose proportionality, in 
the mouse strain used in efficacy studies and, the in 
vivo dose-dependent response on different CML 
models to OR1001. However, our data have already 
validated the rational approach to design new 
compounds active against both c-SRC kinase and 
mutated forms of ABL to counteract TKI-resistance in 
CML. Our findings strongly suggest that OR1001 
could be a good therapeutic option for TKI-resistant 
CML patients. 
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